Pure Global
NCT05273333

Effect of Ultra-gyn® on Vulvovaginal Candidiasis

Biocodex·ClinicalTrials.gov·device·Device trialRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Vulvovaginal Candidiasis, Genital
Drug/Device/Intervention
Ultra-gyn®
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Biocodex
Location
Quatre Bornes, Mauritius
Timeline & enrollment
Phase
N/A
Start date
Feb 23, 2022
End date
Dec 01, 2022
Enrollment
30 participants
Primary outcome

To assess the effect of Ultra-gyn® in relieving the symptoms of Vulvovaginal Candidiasis

Summary

The aim of this post-market clinical follow up study is to confirm the performance and the
 safety of Ultra-gyn® (when used in accordance with its approved labelling)

ICD-10 classifications
Candidiasis of vulva and vaginaCandidiasis, unspecifiedCandidiasisCandidiasis of other urogenital sitesAbscess of vulva
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05273333
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT05273333 through Pure Global AI's free database. This phase not specified trial is sponsored by Biocodex and is currently Recruiting. The study focuses on Vulvovaginal Candidiasis, Genital. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.